Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers

Journal: Nature Medicine

Published: 2020-04-07

DOI: 10.1038/s41591-020-0800-0

Affiliations: 55

Authors: 354

Go to article
Institutions Share
Institute for Molecular Medicine Finland (FIMM), Finland 0.13
Genentech, Inc., United States of America (USA) 0.10
AbbVie Inc., United States of America (USA) 0.09
Merck & Co., Inc., United States of America (USA) 0.06
National Institute for Health and Welfare (THL), Finland 0.06
Pfizer Inc., United States of America (USA) 0.06
The Hospital District of Helsinki and Uusimaa (HUS), Finland 0.06
GlaxoSmithKline plc. (GSK), United Kingdom (UK) 0.04
Northern Savo Hospital District, Finland 0.04
Pirkanmaa Hospital District, Finland 0.04
Sanofi, France 0.03
Biogen Inc., United States of America (USA) 0.03
Northern Ostrobothnia Hospital District (NOHD), Finland 0.03
Celgene Corporation, United States of America (USA) 0.03
Hospital District of Southwest Finland, Finland 0.03
Northern Finland Biobank Borealis, Finland 0.03
AstraZeneca plc, United Kingdom (UK) 0.02
Business Finland, Finland 0.02
Auria Biobank, Finland 0.01
Broad Institute of MIT and Harvard, United States of America (USA) 0.01
Blood Service Biobank, Finland 0.01
Central Finland Biobank, Finland 0.01
Central Finland Health Care District, Finland 0.01
University of Helsinki, Finland 0.01
Finnish Hematology Registry (FHR), Finland 0.01
Biobank of Eastern Finland, Finland 0.01
Tampere University Hospital (TAUH), Finland 0.01
Tampere University, Finland 0.01
Helsinki Biobank, Finland 0.01
Massachusetts General Hospital (MGH), United States of America (USA) 0
Stanford University, United States of America (USA) 0
University of Tartu (UT), Estonia 0
Harvard University, United States of America (USA) 0

Return